ReviewEuropean respiratory review : an official journal of the European Respiratory Society2010
Impact of exacerbations on COPD.
Review in European respiratory review : an official journal of the European Respiratory Society, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07629869 (The Role of COPD Flare-up Clinic Service After Severe Exacerbations to Reduce Recurrent Exacerbations), which is not on this map. Cited by 181 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Role of COPD Flare-up Clinic Service After Severe Exacerbations to Reduce Recurrent Exacerbations
Who cites it
181 citing papers in PubMed, 9 syntheses or guidelines pooled it, 357 citations in OpenAlex.
- COPD-patients' perspective on adherence to therapy and its integration into a systematic literature review.BMC pulmonary medicine · 2026Pooled it
- Efficacy of Carbocisteine in Reducing Exacerbations in Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Advances in respiratory medicine · 2025Pooled it
- Red cell distribution width related to the severity of the disease in patients with AECOPD.Biomarkers in medicine · 2025Pooled it
- Remote Patient Monitoring and Machine Learning in Acute Exacerbations of Chronic Obstructive Pulmonary Disease: Dual Systematic Literature Review and Narrative Synthesis.Journal of medical Internet research · 2024Pooled it
- Magnesium sulfate for acute exacerbations of chronic obstructive pulmonary disease.The Cochrane database of systematic reviews · 2022Pooled it
- Efficacy of ICS versus Non-ICS Combination Therapy in COPD: A Meta-Analysis of Randomised Controlled Trials.International journal of chronic obstructive pulmonary disease · 2022Pooled it
- Design of pulmonary rehabilitation programmes during acute exacerbations of COPD: a systematic review and network meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2020Pooled it
- Thoracic Imaging at Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review.International journal of chronic obstructive pulmonary disease · 2020Pooled it
- Fixed-Dose Combinations of Long-Acting Bronchodilators for the Management of COPD: Global and Asian Perspectives.Advances in therapy · 2019Pooled it
- InforMing the PAthway of COPD Treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations.Respiratory research · 2021Trial
- Trial
- Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study.International journal of chronic obstructive pulmonary disease · 2017Trial
- Long-term integrated telerehabilitation of COPD Patients: a multicentre randomised controlled trial (iTrain).BMC pulmonary medicine · 2016Trial
- Trial
- Prevention of exacerbations in patients with COPD and vitamin D deficiency through vitamin D supplementation (PRECOVID): a study protocol.BMC pulmonary medicine · 2015Trial
- Tiotropium and Salmeterol in COPD Patients at Risk of Exacerbations: A Post Hoc Analysis from POET-COPD(®).Advances in therapy · 2015Trial
- Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study.International journal of chronic obstructive pulmonary disease · 2015Trial
- Fluticasone propionate/salmeterol 250/50 μg versus salmeterol 50 μg after chronic obstructive pulmonary disease exacerbation.Respiratory research · 2014Trial
- Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Exacerbation Outcomes in Patients with COPD without a Recent Exacerbation History: A Subgroup Analysis of KRONOS.International journal of chronic obstructive pulmonary diseaseTrial
- Phase III LUNA clinical programme: design of four randomised, double-blind, placebo-controlled studies assessing the efficacy and safety of tozorakimab in patients with symptomatic COPD and a high risk of exacerbations.BMJ open respiratory research · 2026Article
121 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Exacerbations of chronic obstructive pulmonary disease (COPD) determine disease-associated morbidity, mortality, resource burden and healthcare costs. Acute exacerbation care requirements range from unscheduled primary care visits to emergency room, inpatient or intensive care, generating significant costs in COPD. Even after an exacerbation resolves, respiratory, physical, social and emotional impairment may persist for prolonged time. Frequent exacerbations, mainly in patients with severe COPD, accelerate disease progression and mortality. Thus, patients with frequent exacerbations have a more rapid decline in lung function, worse quality of life and decreased exercise performance. Management of COPD directed to reduce incidence and severity of exacerbations improves long-term health status and conserves health care resources and costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.